Crossmark

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-018-4893-5

Published Online: 2018-10-23

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jacinto, Alexandre Arthur https://orcid.org/0000-0002-6353-2202
Batalha Filho, Eronides Salustiano

Viana, Luciano de Souza

De Marchi, Pedro

Capuzzo, Renato de Castro

Gama, Ricardo Ribeiro

Boldrini Junior, Domingos

Santos, Carlos Roberto

Pinto, Gustavo Dix Junqueira

Dias, Josiane Mourão

Canton, Heloisa Pelisser

Carvalho, Raiany

Radicchi, Lucas Augusto

Bentzen, Soren

Zubizarreta, Eduardo

Carvalho, Andre Lopes
License Information

Text and Data Mining valid from 2018-10-23
More Information

Article History

Received: 21 January 2018

Accepted: 3 October 2018

First Online: 23 October 2018

Ethics approval and consent to participate

: The study entitled “Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma” was conducted according to the Helsinky declaration. The protocol was approved by the Internal Review Board of the Barrretos Cancer Hospital/Fundação PIO XII and it is registered inthe Brazilian Platform of Ethics in Research () under the registration Number <b>CAAE:</b> 32147014.4.0000.5437. All patients provided specific written informed consent prior to participating in this trial. The study was also registered at under the number NCT03194061.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.